Combination of PIM and JAK2 inhibitors synergistically suppresses cell proliferation and overcomes drug resistance of myeloproliferative neoplasms-Reference-Cited by-同舟云学术

Combination of PIM and JAK2 inhibitors synergistically suppresses cell proliferation and overcomes drug resistance of myeloproliferative neoplasms

Published:2014-05-08 Issue:10 Volume:5 Page:3362-3374
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Huang Shih-Min A.¹²,Wang Anlai¹,Greco Rita¹,Li Zhifang¹,Sun Fangxian¹,Barberis Claude³,Tabart Michel⁴,Patel Vinod³,Schio Laurent⁴,Hurley Raelene¹,Chen Bo⁵,Cheng Hong¹,Lengauer Christoph¹⁶,Pollard Jack¹,Watters James¹,Garcia-Echeverria Carlos⁴,Wiederschain Dmitri¹,Adrian Francisco¹,Zhang JingXin¹

Affiliation:

1. Sanofi Oncology, Cambridge, MA, 02139, USA

2. Current affiliation: Genentech, 1 DNA way, South San Francisco, CA, 94080, USA

3. Sanofi, Lead Generation and Candidate Realization, Waltham, MA USA

4. Sanofi Oncology, Discovery and Early Development, Vitry-Sur-Seine, France

5. Sanofi- Genzyme, GDB, Cambridge, MA, 02139, USA

6. Current affiliation: Blueprint Medicines, Cambridge, MA 02140, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC–Alarmin Axis;Blood Cancer Discovery;2024-05-07

2. A Novel Subtype of Myeloproliferative Neoplasms Driven by a MYC-Alarmin Axis;2023-09-26

3. An overview of pim kinase as a target in multiple myeloma;Cancer Medicine;2023-05

4. Circulating CD133+/–CD34– Have Increased c-MYC Expression in Myeloproliferative Neoplasms;Turkish Journal of Hematology;2023-03-03

5. Targeting Pim kinases in hematological cancers: molecular and clinical review;Molecular Cancer;2023-01-25